The company’s initial commercial programs in mainland China expand its geographic reach and mark a new step in the global rollout of its human tissue-based drug testing platform.
Key Investor Takeaways – VivoSim (NASDAQ:VIVS) secured its first commercial sales in mainland China through two paid customer engagements. – The VivoSim China commercial sales expand the company’s NAMkind™ toxicology and efficacy testing platform into one of the world’s largest pharmaceutical markets. – The initial contracts cover gastrointestinal toxicology screening and efficacy profiling for drug candidates in oncology and other disease areas. – Management said the two engagements represent a meaningful portion of the company’s contracted revenue to date. – Investors will be watching whether these initial programs lead to additional commercial customers and broader adoption across the Asia-Pacific region
Why VIVS Stock Is in Focus VivoSim announced its first commercial sales in mainland China through two paid testing programs secured by its local distributor, Tekon. The engagements involve a Shanghai-based oncology biotechnology company and a pharmaceutical company headquartered in Chengdu. The projects cover gastrointestinal toxicology screening and NAMkind™ gastrointestinal efficacy testing for candidate therapies and represent VivoSim’s first paid commercial work in China.
According to the company, the contracts account for a meaningful share of its contracted revenue to date and establish a commercial presence in the Chinese market. Management estimates the addressable Chinese market for liver and gastrointestinal in vitro models and toxicology services at approximately $2 billion, with projected annual growth of around 10%. VivoSim said increasing regulatory acceptance of scientifically validated non-animal testing approaches could support wider adoption of its human tissue-based models. “China is now the world’s second-largest pharmaceutical market and among the fastest-moving…